Stock has rallied 32.6% over the past year, outperforming the S&P 500. Company shows strong growth momentum across multiple channels, double-digit growth in advanced diagnostics, and successful execution of cost-saving initiatives. Zacks Rank #2 (Buy) rating with consistent earnings beat history (5.8% average surprise).
Strong earnings performance with four consecutive quarters of beating consensus estimates, 42.4% year-to-date gain, Zacks Rank #2 (Buy) rating, and solid growth projections (13.2% EPS growth expected for current fiscal year). However, valuation is at a premium to peers, which tempers the outlook.
The CEO's sale is characterized as routine and non-concerning, executed under a pre-planned trading arrangement for personal liquidity needs rather than reflecting concerns about company fundamentals. The company shows solid operational performance with 10% YoY revenue growth, stable mid-teens operating margins, and anticipated 8% annualized earnings growth. The stock has delivered 32% returns over the past 12 months.
Quest is portrayed negatively for acquiring LifeLabs and subsequently reducing services in Ontario, closing/reducing staffing at facilities, transferring lab tests to the U.S., compromising patient privacy, delaying results, reducing hospital efficiency, and prioritizing corporate profits over quality patient care.
The declaration of a quarterly cash dividend demonstrates financial strength and confidence in the company's cash flow generation. Regular dividend payments are a positive signal to investors, indicating the company's ability to return capital to shareholders while maintaining operations.
The company demonstrated strong financial health and commitment to shareholder returns through a 7.5% dividend increase (15th consecutive year) and a substantial $1 billion increase in share repurchase authorization. These actions indicate confidence in the company's cash generation and business outlook.
Articles that tag DGX but are mainly about other companies.
Included as a key market player but no specific developments or market activities highlighted in the article.
Stock returned 26.4% over 12 weeks as part of the Earnings Certain Dividend Portfolio (ECDP)
Increased 18.4% over 12 weeks as part of Earnings Certain Dividend Portfolio; benefited from investor preference for quality dividend stocks.
Identified as a key market participant and large-scale reference laboratory operator best positioned to capture outsourcing tailwinds and benefit from digital automation efficiencies in the growing pathology services market.
Quest Diagnostics is identified as a leading company in the blood-based biomarkers market with significant diagnostic laboratory capabilities.
Listed among key market participants in cancer biomarker testing, positioned to capture market share in the expanding precision oncology diagnostics sector.
Launched FDA-cleared HPV self-collection service in April 2025, demonstrating active market participation and innovation
Major drug testing laboratory operator positioned to benefit from sustained market growth driven by workplace policies, healthcare protocols, and regulatory oversight across multiple regions.
Identified as major market player but lacks specific recent developments or strategic initiatives detailed in the article.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
